Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Creteil – page 27

634 clinical trials in Creteil, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Creteil at a glance
634
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

634 trials in Creteil

Open in trial search

Acute myeloid leukaemia

Not yet recruiting

A Study of Ivosidenib and Azacitidine for Patients Over 55 with Acute Myeloid Leukemia and IDH1 Mutation in Complete Remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Anti-neutrophil cytoplasmic antibody positive vasculitis

Not yet recruiting

Testing avacopan added to standard treatment in patients with ANCA-associated vasculitis with severe kidney damage

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avacopan
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Systemic candida

Not yet recruiting

Study comparing 7-day versus 14-day antifungal treatment for patients with uncomplicated candidemia using fluconazole, anidulafungin, or other medications

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anidulafungin
  • Sponsor:Assistance Publique Hopitaux De Paris

Sepsis

Not yet recruiting

Testing rasburicase for preventing and treating kidney problems in adult patients with sepsis and high uric acid levels

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rasburicase
  • Sponsor:Assistance Publique Hopitaux De Paris

Acquired ATTR amyloidosis

Not yet recruiting

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Erysipelas

Not yet recruiting

Comparison of compression therapy alone versus compression therapy with phenoxymethylpenicillin for preventing recurrent erysipelas in lower limbs

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Cutaneous T-cell lymphoma

Not yet recruiting

Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Assistance Publique Hopitaux De Paris

Liver abscess

Not yet recruiting

Study comparing 3-week versus 6-week antibiotic treatment for patients with drained pyogenic liver abscess

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Assistance Publique Hopitaux De Paris

Neovascular age-related macular degeneration

Not yet recruiting

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Renal cancer

Not yet recruiting

Study of Nivolumab and Ipilimumab or Drug Combination for Patients with Metastatic Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:ARTIC

Evaluation of Methylprednisolone and Prednisone in Adult Patients with Acute Myocarditis and Reduced Heart Function

Not yet recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Creteil

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Groundbreaking studies focusing on TTR amyloidosis and heart disease treatments, evaluating novel therapeutic approaches for cardiac conditions. Research includes assessment of innovative medications for chronic kidney disease with hypertension.

  • TTR Amyloidosis Cardiomyopathy
  • Chronic Kidney Disease
  • Hypertension Management
02 Neurological Disorders

Comprehensive research into various neurological conditions, including innovative studies on Huntington's disease biomarkers and treatment approaches for essential tremor and Parkinson's disease.

  • Huntington's Disease Progression
  • Essential Tremor Treatment
  • Parkinson's Disease Management
03 Oncology & Hematology

Advanced clinical trials in blood cancers and solid tumors, including studies of multiple myeloma treatments and novel approaches for non-small cell lung cancer and mesothelioma.

  • Multiple Myeloma Therapies
  • Acute Myeloid Leukemia
  • Lung Cancer Treatment
04 Autoimmune Conditions

Innovative treatments for inflammatory and autoimmune disorders, investigating new therapies for Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

  • Inflammatory Bowel Disease
  • Rheumatoid Arthritis Management
  • Microbiota Transplantation Studies
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.